Göttingen, Germany

Monika Ostertag


Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 62(Granted Patents)


Location History:

  • Gottingen, DE (2000)
  • Göttingen, DE (2005)

Company Filing History:


Years Active: 2000-2005

Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Monika Ostertag: Innovator in Contraceptive Solutions**

Introduction

Monika Ostertag, an accomplished inventor based in Göttingen, Germany, has made significant contributions to the field of contraceptive solutions. With a total of two patents to her name, Ostertag is recognized for her innovative approach to hormonal contraception, focusing on natural estrogens.

Latest Patents

Ostertag's latest patents revolve around a combination preparation for contraception that is based on natural estrogens. The first patent outlines that the combination preparation includes from 2 to 4 first stage daily dosage portions, each containing an effective amount of at least one natural estrogen as the sole active ingredient. This is followed by a second stage that comprises 16 to 22 daily dosage portions, which are a combination of at least one natural estrogen and a natural or synthetic gestogen as active ingredients. The third stage similarly includes 2 to 4 daily dosage portions with an effective amount of a natural estrogen, and the final stage consists of 2 to 4 daily dosage portions containing a pharmaceutically acceptable placebo. The estrogens in this preparation may include estradiol or its compounds, along with other forms such as conjugated equine estrogens or phytoestrogens. The gestogen component can either be natural progesterone or synthetic forms such as medroxyprogesterone acetate.

The second patent showcases a similar combination preparation, detailing multiple stages of dosage that balance the effective amounts of natural estrogen and gestogens, ensuring a well-structured approach to hormonal contraception.

Career Highlights

Ostertag's innovative work in contraception has been pivotal in advancing hormonal therapies that utilize natural compounds. Her dedication to research and development in this area is reflected in the successful patents that contribute to more effective and safer contraceptive methods.

Collaborations

Throughout her career, Monika Ostertag has collaborated with esteemed colleagues, including Michael Dittgen and Sabine Fricke. These partnerships have allowed for a fusion of ideas and expertise, enhancing the innovative capacity within their projects at Jenapharm GmbH & Co. KG.

Conclusion

Monika Ostertag stands out as a pioneering inventor within the contraceptive health sphere. Her patents not only highlight innovative approaches to hormonal contraception but also reflect her commitment to improving women's health solutions. Through her work at Jenapharm GmbH & Co. KG and collaborative efforts with her colleagues, Ostertag continues to shape the future of contraceptive methods.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…